Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Tandem Diabetes Care Inc (NASDAQ: TNDM) was $20.51 for the day, down -2.38% from the previous closing price of $21.01. In other words, the price has decreased by -$2.38 from its previous closing price. On the day, 2.12 million shares were traded. TNDM stock price reached its highest trading level at $20.53 during the session, while it also had its lowest trading level at $19.326.
Ratios:
Our analysis of TNDM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.44. In the meantime, Its Debt-to-Equity ratio is 3.38 whereas as Long-Term Debt/Eq ratio is at 3.22.
On September 08, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22. Citigroup Upgraded its Sell to Neutral on August 12, 2025, while the target price for the stock was maintained at $10.35.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 11 ’25 when Sheridan John F bought 10,000 shares for $10.23 per share. The transaction valued at 102,318 led to the insider holds 106,327 shares of the business.
Vosseller Leigh bought 13,720 shares of TNDM for $149,404 on Aug 08 ’25. The EVP & CHIEF FINANCIAL OFFICER now owns 25,580 shares after completing the transaction at $10.89 per share. On Mar 07 ’25, another insider, Kyrillos Jean-Claude, who serves as the EVP & Chief Operating Officer of the company, bought 10,538 shares for $18.12 each. As a result, the insider paid 190,966 and bolstered with 10,538 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 1390626432 and an Enterprise Value of 1525699328. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.38 while its Price-to-Book (P/B) ratio in mrq is 10.45. Its current Enterprise Value per Revenue stands at 1.515 whereas that against EBITDA is -21.927.
Stock Price History:
The Beta on a monthly basis for TNDM is 1.69, which has changed by -0.37039256 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, TNDM has reached a high of $38.28, while it has fallen to a 52-week low of $9.98. The 50-Day Moving Average of the stock is 30.36%, while the 200-Day Moving Average is calculated to be 16.96%.
Shares Statistics:
TNDM traded an average of 2.09M shares per day over the past three months and 2790620 shares per day over the past ten days. A total of 67.77M shares are outstanding, with a floating share count of 67.09M. Insiders hold about 1.05% of the company’s shares, while institutions hold 112.45% stake in the company. Shares short for TNDM as of 1763078400 were 8787092 with a Short Ratio of 4.19, compared to 1760486400 on 9237943. Therefore, it implies a Short% of Shares Outstanding of 8787092 and a Short% of Float of 17.930001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 19.0 analysts currently analyzing and rating the stock of Tandem Diabetes Care Inc (TNDM).The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.2 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.5 and -$3.32 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$0.96, with 22.0 analysts recommending between -$0.42 and -$2.39.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 20 analysts. It ranges from a high estimate of $281.86M to a low estimate of $271.43M. As of. The current estimate, Tandem Diabetes Care Inc’s year-ago sales were $282.65MFor the next quarter, 20 analysts are estimating revenue of $248.88M. There is a high estimate of $261.79M for the next quarter, whereas the lowest estimate is $232.28M.
A total of 23 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $1.01B, while the lowest revenue estimate was $995.78M, resulting in an average revenue estimate of $1B. In the same quarter a year ago, actual revenue was $940.2MBased on 23 analysts’ estimates, the company’s revenue will be $1.1B in the next fiscal year. The high estimate is $1.14B and the low estimate is $1.07B.
